Innate Pharma S.A. (EPA:IPH)

France flag France · Delayed Price · Currency is EUR
1.838
-0.110 (-5.65%)
Oct 17, 2025, 5:35 PM CET
-5.65%
Market Cap169.40M
Revenue (ttm)12.64M
Net Income (ttm)-46.05M
Shares Out92.17M
EPS (ttm)-0.55
PE Ration/a
Forward PE7.91
Dividendn/a
Ex-Dividend Daten/a
Volume259,306
Average Volume268,623
Open1.910
Previous Close1.948
Day's Range1.828 - 1.942
52-Week Range1.330 - 2.500
Beta0.80
RSI56.85
Earnings DateDec 19, 2025

About Innate Pharma

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 181
Stock Exchange Euronext Paris
Ticker Symbol IPH
Full Company Profile

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.

Financial Statements

News

Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an analyst and ...

4 days ago - Business Wire

This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...

4 weeks ago - Benzinga

IPHA: Leerink Partners Downgrades Innate Pharma, Lowers Price Target | IPHA Stock News

IPHA: Leerink Partners Downgrades Innate Pharma, Lowers Price Target | IPHA Stock News

4 weeks ago - GuruFocus

Innate Pharma (IPHA) Downgrade: What Investors Need to Know | IPHA Stock News

Innate Pharma (IPHA) Downgrade: What Investors Need to Know | IPHA Stock News

4 weeks ago - GuruFocus

Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ...

Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial Resilience Amidst Challenges

4 weeks ago - GuruFocus

Half Year 2025 Innate Pharma SA Earnings Call Transcript

Half Year 2025 Innate Pharma SA Earnings Call Transcript

4 weeks ago - GuruFocus

Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript

Discover Innate Pharma’s H1 2025 results, strategic pipeline focus, and updates on key

4 weeks ago - Seeking Alpha

Innate Pharma S.A. 2025 Q2 - Results - Earnings Call Presentation

2025-09-17. The following slide deck was published by Innate Pharma S.A.

4 weeks ago - Seeking Alpha

Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops

(RTTNews) - Innate Pharma S.A. (IPHA, IPH.PA), a French biotechnology firm, on Wednesday reported a narrower first-half net loss mainly aided by reduced expenses, amid weak revenues.

4 weeks ago - Nasdaq

Earnings Scheduled For September 17, 2025

Companies Reporting Before The Bell • 111 (NASDAQ: YI) is likely to report earnings for its second quarter. • Innate Pharma (NASDAQ: IPHA) is likely to report earnings for its first quarter. • Gener...

4 weeks ago - Benzinga

Innate Pharma Reports First Half 2025 Business Update and Financial Results

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Innate Pharma Reports First Half 2025 Business Update And Financial Results.

4 weeks ago - Business Wire

Innate Pharma SA (IPHA) Q2 2025 Earnings Report Preview: What To Look For

Innate Pharma SA (IPHA) Q2 2025 Earnings Report Preview: What To Look For

4 weeks ago - GuruFocus

Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces its participation in the 25th edition of the European Midcap Event.

4 weeks ago - Business Wire

Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma announces conference call and webcast for first half 2025 financial results and business update.

5 weeks ago - Business Wire

Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference

MARSEILLE, France--(BUSINESS WIRE)-- #IRConference--Innate Pharma announces its participation in BTIG virtual biotechnology conference.

2 months ago - Business Wire

Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences

MARSEILLE, France--(BUSINESS WIRE)-- #InvestorRelations--Innate Pharma announces its participation in H.C. Wainwright and Wolfe Research Healthcare Conferences.

4 months ago - Business Wire

Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for ...

4 months ago - Business Wire

Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

MARSEILLE, France--(BUSINESS WIRE)-- #IRConferences--Innate Pharma announces its participation in upcoming investor conferences.

5 months ago - Business Wire

Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term fol...

5 months ago - Business Wire

Outcome of Innate Pharma's 2025 Annual General Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #AG--Outcome of Innate Pharma's 2025 Annual General Meeting.

5 months ago - Business Wire

Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate's drugs i...

5 months ago - Business Wire

Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its A...

5 months ago - Business Wire